生物试剂
>
生化试剂
>
信号通路
> LV-320
加入收藏 取消收藏

LV-320  ≥95%

促销价¥{{model.attbuying.price}}

市场价¥0.00

累计销量0 累计评价0 人评论

别称 {{model.alias}}
中文名称 {{model.name}}
英文名称 {{model.enname}}
品牌 {{model.brand}}
CAS {{model.cas}}
分子式
分子量 {{model.molecularweight}}
MDL {{model.mdl}}
货号 {{model.procode}}
数量

+ -

件 库存{{model.attbuying.number}}件
立即购买 加入购物车 下载说明书

看了又看
包装规格：1mg 5mg in glass bottle
溶解性：溶于DMSO（135 mg/mL 超声）
产品描述：基本信息 产品编号：L10363 产品名称：LV-320 CAS: 2449093-46-1   储存条件 粉末 -20℃ 四年     分子式： C29H26ClNO2S2 溶于液体 -80℃ 六个月 分子量 520.11 -20℃ 一个月 化学名：  3-[[4-[(E)-2-(7-chloroquinolin-4-yl)ethenyl]phenyl]-(2-phenylethylsulfanyl)methyl]sulfanylpropanoic acid   Solubility (25°C)   体外 DMSO 100mg/mL (192.27mM; Need ultrasonic) Ethanol   Water   体内 现配现用   ＜1mg/ml表示微溶或不溶。 普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。   制备储备液   浓度   溶液体积 质量   1mg   5mg   10mg 1mM 1.9227mL 9.6134mL 19.2267mL 5mM 0.3845mL 1.9227mL 3.8453mL 10mM 0.1923mL 0.9613mL 1.9227mL   生物活性 产品描述 一种有效且非竞争性的 ATG4B 抑制剂，其 IC50 值为 24.5μM，Kd 值为 16μM。 靶点/IC50 IC50: 24.5µM (ATG4B); Kd: 16μM (ATG4B)   体外研究 LV-320 (0-120 µM; SKBR3, MCF7, JIMT1, and MDA-MB-231 cells) treatment results in a dose-dependent increase in endogenous LC3B-II and protein p62 levels in all four cell lines. LV-320 (120 µM; 48 hours; MDA-MB-231 cells) treatment results in an increase in LC3B-II, indicating that LV-320 blocks autophagic flux. Western Blot Analysis Cell Line: SKBR3, MCF7, JIMT1, and MDA-MB-231 cells Concentration: 0 µM, 25 µM, 50 µM, 75 µM, 100 µM, or 120 µM Incubation Time:   Result: Resulted in a dose-dependent increase in endogenous LC3B-II and protein p62 levels in all four cell lines. Cell Autophagy Assay Cell Line: MDA-MB-231 cells Concentration: 120 µM Incubation Time: 48 hours Result: Blocked autophagic flux.   体内研究 LV-320 (100-200 mg/kg; oral gavage; three times over two days; GFP-LC3 mice) treatment results in a terminal blood level of 169 µM and a liver level of 104 µM. The expression of GFP-LC3 puncta is significantly greater accumulation in LV-320 treated animals compared to controls. LC3B-II protein is also increased in LV-320-treated animals. The treatment do not cause significant toxicity in mice at either dose. Animal Model: GFP-LC3 mice (females, 9-14 weeks) Dosage: 100mg/kg or 200mg/kg Administration: Oral gavage; three times over two days (Pharmacokinetic study) Result: Terminal blood levels were 169 µM and liver levels were 104 µM. LC3B-II protein level was also increased.
保存条件：-20℃

猜你喜欢